- Home
- A-Z Publications
- Current Drug Targets - Inflammation & Allergy
- Previous Issues
- Volume 1, Issue 2, 2002
Current Drug Targets - Inflammation & Allergy - Volume 1, Issue 2, 2002

Volume 1, Issue 2, 2002
-
-
The Glucocorticoid Receptor: Molecular Mechanism and New Therapeutic Opportunities
Authors: L. Buckbinder and R.P. RobinsonSynthetic glucocorticoids are among the most effective anti-inflammatory drugs available. The activity of this drug class is mediated by the glucocorticoid receptor, a nuclear steroid receptor whose endogenous ligand is the adrenal hormone cortisol. Chronic glucocorticoid treatment is accompanied by serious side-effects, reflecting the symptoms of cortisol excess seen in Cushing's syndrome patients. During the past 50 Read More
-
-
-
Upstream Signal Transduction of NF-κB Activation
Authors: F. Chen, L.M. Demers and X. ShiNF-κB is a transcription factor governing the expression of genes involved in the immune response, embryo or cell lineage development, cell apoptosis, cell cycle progression, inflammation, and oncogenesis. During the past few years, considerable attention has been paid to the upstream signaling pathways that lead to the activation of NF-κB. Many of these signaling molecules can serve as potential pharmaceutical targets Read More
-
-
-
Current and Future Therapeutic Strategies to Target Inflammation in Stroke
Authors: W. Zhang and D. StanimirovicExperimentally and clinically, stroke is followed by both acute and prolonged inflammatory responses characterized by the production of inflammatory cytokines and leukocyte infiltration into the brain. A debate on whether inflammation after stroke is neurotoxic or participates in brain repair remains unresolved. However, the need to pharmacologically control inflammatory amplification has been commonly acknowled Read More
-
-
-
Mechanisms of Antihistamines and Mast Cell Stabilizers in Ocular Allergic Inflammation
Authors: E.B. Cook, J.L. Stahl, N.P. Barney and F.M. GrazianoMast cells play a central role in allergic reactions and inflammation. Successful anti-allergic therapies have typically targeted mast cell mediators, particularly histamine. Antihistaminic compounds interact with the various histamine receptors found on many cells, whereas other compounds such as disodium cromoglycate, are referred to as mast cell stabilizers, as they inhibit degranulation. Some of the most successful comp Read More
-
-
-
Toll-Like Receptors and Inflammation in the CNS
Authors: S. Joong Lee and S. LeeThe innate immune system recognizes “non-self” by employing a set of germline-encoded receptors called Toll-like receptors (TLRs), originally characterized in Drosophila. TLRs are involved in the recognition of various microbial-derived molecules, including lipopolysaccharide (LPS), lipoteichoic acid (LTA), and peptidoglycan (PGN), as well as unmethylated bacterial DNA. The TLR-mediated intracellular signaling pathwa Read More
-
-
-
Cytokines in Dementias
By E. TarkowskiKnowledge regarding putative inflammatory component(s) participating in Alzheimer's disease (AD) and in vascular dementia (VAD) remains scarce. Recently, we have demonstrated the presence of inflammatory components, such as cytokines, in the CSF of demented patients. Although the initial events triggering the neurodegenerative processes in AD versus VAD may be different and thus lead to different neuropatholo Read More
-
-
-
Eotaxin Receptor (CCR3) Antagonism in Asthma and Allergic Disease
Authors: E.M. Erin, T.J. Williams, P.J. Barnes and T.T. HanselA range of low molecular weight chemicals have been developed to antagonise the eotaxin receptor, cysteine-cysteine chemokine receptor-3 (CCR3), with the aim of selectively inhibiting eosinophil recruitment into tissue sites. However, the results of recent clinical trials with monoclonal antibodies directed against interleukin-5 (IL-5) question the role of eosinophils in mediating the symptoms of asthma and allergic diseas Read More
-
Volumes & issues
Most Read This Month
Article
content/journals/cdtia
Journal
10
5
false
en
